Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an update.
BioArctic AB reported a significant increase in royalties from the sales of Leqembi®, with third-quarter 2025 sales reaching 18 billion yen, resulting in a 68% increase in royalties compared to the previous year. This growth underscores the successful commercialization of Leqembi, a key product in BioArctic’s portfolio, and highlights the company’s strong position in the Alzheimer’s treatment market, with ongoing collaborations and clinical studies further supporting its industry standing.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company specializing in innovative treatments for neurodegenerative diseases. The company is known for inventing Leqembi® (lecanemab), a groundbreaking drug that slows the progression of early Alzheimer’s disease. BioArctic collaborates with Eisai for the global commercialization and regulatory processes of Leqembi. Besides Alzheimer’s, BioArctic’s research portfolio includes projects targeting Parkinson’s disease and ALS, utilizing their proprietary BrainTransporter™ technology to enhance treatment efficacy.
Average Trading Volume: 314,983
Technical Sentiment Signal: Buy
Current Market Cap: SEK26.24B
For a thorough assessment of BIOA.B stock, go to TipRanks’ Stock Analysis page.